Liranaftate is a squalene epoxidase inhibitor with anti-fungicidal activities. Liranaftate showed excellent fungistatic activity against the conidia of T. rubrum. For each of these agents, the MIC after 14 days of contact was 0.009 g/ml. The liranaftate-induced decrease in the MCC occurred from 9 days onwards; MCC at 14 days was 0.039 g/ml[3]. Liranaftate with its potent fungicidal activities was suggested an efficacious agent for the treatment of dermatophytes[4]. Luliconazole was also highly active against Candida albicans (MIC range: 0.031-0.13 microg/ml), proving to be more potent than terbinafine, liranaftate, butenafine, amorolfine, and bifonazole, but less than ketoconazole, clotrimazole, neticonazole, and miconazole. Further, the MIC of luliconazole against Malassezia restricta, an important pathogenic agent involved in seborrhoeic dermatitis, was very low (MIC range: 0.004-0.016 microg/ml) suggesting action comparable to or stronger than that of ketoconazole[5]. Topical 20 microl administration of liranaftate in a dose-range between 1-4% suppressed the increase in ear thickness 6 hr after PMA (phorbol 12-myristate 13-acetate) application dose-dependently[6]. Clinically, liranaftate an antifungal drug with IL-8-decreasing activity may reduce infiltration of neutrophils in the skin and their invasion into the epidermis[7].
搜索
